Summary: Fraxetin, a major constituent of the traditional medicine plant Fraxinus rhynchophylla Hance (Oleaceae), has been found to possess multiple bioactivities. However, the metabolic pathway(s) of fraxetin in human tissues has not been reported yet. This study aimed to characterize the glucuronidation pathway(s) of fraxetin in human tissues. Fraxetin could be metabolized to two glucuronides in human liver microsomes (HLMs). These two glucuronides were biosynthesized and characterized as 7-O-glucuronide (7-O-G) and 8-O-glucuronide (8-O-G). UGT1A1, -1A6, -1A7, -1A8, -1A9 and -1A10 participated in the formation of 7-O-G, while the formation of 8-O-G was catalyzed selectively by UGT1A6 and UGT1A9. UGT1A9 showed the highest catalytic activities in the formation of 7-O-G and 8-O-G. Both kinetic characterization and inhibition assays demonstrated that UGT1A9 played important roles in fraxetin glucuronidations in HLMs, especially in the formation of the major metabolite 8-O-G. Furthermore, the intrinsic clearance of fraxetin in both human liver microsomes and UGT1A9 was greater than that of 7,8-dihydroxylcoumarin, revealing that the addition of a C-6 methoxy group led to the higher metabolic clearance. In summary, the glucuronidation pathways of fraxetin in human liver microsomes were well-characterized, and UGT1A9 was the major isoform responsible for the glucuronidations of fraxetin.
Introduction
Fraxetin (Fig. 1) , one of major constituents of the traditional medicinal plant Fraxinus rhynchophylla Hance (Oleaceae), has been found with multiple bioactivities including scavenging effects against reactive oxygen species and inhibited lipid peroxidation in the rat brain. 1, 2) Recent studies have demonstrated that fraxetin can act as a neuroprotective agent in human neuroblastoma cells and also has potential anti-atherosclerosis effects. 3, 4) Fraxetin and its glucoside fraxin (fraxetin-7-O-¢-glucosidase) are benzo-¡-pyrones skeleton-containing coumarins; they often coexist in traditional Chinese herbals (such as Cortex Fraxini, a widely and traditionally used herb) or products derived from medicinal plants. The amount of fraxin is much higher than that of fraxetin, usually by an order of magnitude. 5) A previous study reported that fraxin (fraxetin-7-O-¢-glucosidase) could be primarily hydrolyzed to fraxetin by intestinal microflora extensively, after oral administration of fraxin in rats. This finding suggested that the aglycone of fraxin (fraxetin) rather than fraxin itself was the major constituent in the circulating system after administration of fraxin-containing herbals, and also implied that the in vivo pharmaceutical effects of fraxin might be attributable to fraxetin or its constitutive metabolite(s).
From the view of chemical structure, fraxetin is a catecholcontaining compound which can be readily metabolized by phase II enzymes and form glucuronide, sulfate, and O-methylated metabolites. Actually, the corresponding sulfate, glucuronide, and methyl-conjugates of fraxetin have been isolated from rat urine after oral administration of fraxin. 6) This finding suggested that the conjugation reactions played a key role in the metabolic elimination of fraxetin. However, the metabolic pathways of fraxetin in human tissues have not been reported yet. Our previous study noted that 7,8-hydroxycoumarin , the structural analog of fraxetin, was a good substrate for human UDP-glucuronosyltransferases (UGTs) with a high hepatic clearance. 7) Additionally, the extensive metabolism of coumarin phenolics including 7-hydroxycoumarin and 4-methylumbelliferone by human UGTs was also reported previously. 8, 9) Therefore, it is necessary to characterize the glucuronidation pathway(s) of fraxetin in human tissues, when considering that the glucuronidation has been recognized as an important metabolic route of most coumarin phenolics.
Identification of major metabolites and involved drug-metabolizing enzymes (DMEs) are very helpful for the elucidation of the real active compound(s) in the human body, and for the understanding of the variations in pharmaceutical effects in vivo. Therefore, the purposes of the present study are (i) to characterize the metabolites of fraxetin and to identify the human UGT isoform(s) responsible for the formation of the generated metabolites, by using recombinant human UGTs and human liver microsomes (HLMs); (ii) to determine the hepatic clearance of fraxetin via the glucuronidation pathway(s) and to investigate the effect of C-6 methoxy on the glucuronidation of fraxetin.
Methods
Chemicals and reagents: Fraxetin (purity > 98%) was purchased from Heowns Biochem (Tianjin, China). Alamethicin, Brij 58, magnesium chloride, D-saccharic acid 1,4-lactone, ¢-glucuronidase (EC No. 3.2.1.31), uridine 5A-diphospho-glucuronic acid trisodium salt (UDPGA), niflumic acid and fluconazole were purchased from Sigma-Aldrich (St. Louis, MO). Magnolol (purity > 98%) was purchased from Scvictory Company (Chengdu, China). Pooled human liver microsomes (HLM) from 25 donors (Lot. DXOV) were purchased from Research Institute for Liver Diseases (Shanghai, China). A panel of recombinant human UGT isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10,  2B4, 2B7, 2B15 , and 2B17) expressed in baculovirus-infected insect cells were purchased from BD Gentest Corp (Woburn, MA). All other reagents were of HPLC grade or of the highest grade commercially available.
Identification of fraxetin glucuronidation in HLM: The incubation mixture (200 µl) contained HLM (0.5 mg protein/ml), 5 mM UDPGA, 5 mM MgCl 2 , 25 µg/ml alamethicin, 10 mM Dsaccharic acid 1,4-lactone, 200 µM fraxetin and Tris-HCl buffer (pH 7.4). After 30 min of incubation at 37°C, the reaction was terminated by the addition of 0.2 ml of acetonitrile, followed by centrifugation at 20,000 © g for 10 min to obtain the supernatant for high performance liquid chromatography spectrometry (HPLC) analysis. Control incubations without UDPGA or without substrate or without microsomes were performed to ensure that the metabolites produced were microsome-and UDPGA-dependent.
To ensure the formation of glucuronide, the hydrolysis of the product in the incubation mixture with ¢-glucuronidase was also performed. After incubation for glucuronidation for 0.5 h in 200 µl reaction mixture (without D-saccharicacid 1,4-lactone), 200 µl 0.15 M acetate buffer (pH 5.0) with/without ¢-glucuronidase (1,800 Fishman units) was added to the reaction mixture, and then the incubation was carried out at 37°C for another 0.5 h. The reaction was quenched by the addition of 200 µl acetonitrile and centrifuged at 20,000 © g for 10 min; the supernatant was analyzed by HPLC-UV.
Analytical instruments and conditions: Fraxetin and its glucuronides were analyzed by an HPLC system (Shimadzu, Kyoto, Japan) containing an SCL-10A system controller, two LC-10AT pumps, a SIL-10A auto-injector, and an SPD-10AVP UV detector. An Acchrom neutral amide analytical column (150.0 mm © 4.6 mm, 5 µm) was used to separate fraxetin and its glucuronides. Column temperature was kept at 40°C. The mobile phase was acetonitrile (A) and water containing 0.2% formic acid (B) at a flow rate of 1 ml/min, with a gradient: 0-10.0 min, 98% B-78% B; 10.0-18 min, 10% B; 18.0-28.0 min, balance to 98% B. The glucuronidation sample was stable over 72 h at 4°C. Fraxetin glucuronidation was quantified by the standard curve of the glucuronide at the detector wavelength of 338 nm, which was linear from 0.1 to 20 µM (the correlation coefficient was 0.999). The quantitative method displayed good sensitivity, with the limit of detections of fraxetin glucuronide below 0.5 ng. The method also displayed good reproducibility, with the intra-day and interday variance both less than 3%.
Mass detection was performed on a Shimadzu LC-MS-2010EV instrument with an ESI interface both in positive and negative ion mode from m/z 100 to 800. The detector voltage was set at +1.55 kV and ¹1.55 kV, for positive and negative ion detection, respectively. The curved desolvation line temperature (CDL) and the block heater temperature were both set at 250°C, while the CDL voltage was set at 40V. Other MS detection conditions were as follows: interface voltage, +4.5 kV and ¹4.0 kV for positive and negative ion detection, respectively; nebulizing gas (N 2 ) flow 1.5 L/min; and the drying gas (N 2 ) pressure 0.06 MPa. Data processing was performed using the LC/MS Solution version 3.41 software (Shimadzu).
Biosynthesis of metabolites and NMR spectrometry: The metabolites were biosynthesized using mixed liver microsomes from rats (RLM) and humans (50% RLM and 50% HLM), and purified for structure elucidation and quantitative analysis. In brief, 1 mM fraxetin was incubated with mixed liver microsomes (0.5 mg protein/ml), 0.1 M Tris-HCl (pH 7.4), 10 mM MgCl 2 , Brij 58 (0.5 mg/mg protein), 10 mM D-saccharic acid 1,4-lactone, and 5 mM UDPGA in 1 ml of final incubations for 4 h at 37°C. The stock solution of fraxetin (100 mM) was prepared in DMSO. The concentration of organic solvent in the final incubation was 1%. The reaction was terminated by transferring the vessel to an ice bath and cooling for 20 min. After removal of protein by centrifugation at 20,000 © g for 30 min at 4°C, the combined supernatants were loaded on a SPE cartridge (C18, 1,000 mg, Agela Technologies, Radnor, PA), which was preconditioned by sequential washing with 6 ml methanol and 6 ml Millipore water. After sample loading, the SPE cartridge was sequentially eluted with 12 ml Millipore water, 12 ml methanol and 12 ml methanol containing 5% formic acid. The entire process was monitored by HPLC, and the metabolite was assembled in methanol containing 5% formic acid. After vacuum evaporation, the residue was redissolved in 1 ml methanol, and purified by HPLC. Finally, 4.0 mg M-1 and 6.8 mg M-2 were obtained and their purities were greater than 96% according to LC-UV analysis. The structures of metabolites were determined by NMR. The experiment was carried on a Varian INOVA-400 NMR spectrometer (Varian, Palo Alto, CA). The purified metabolites were stored at ¹20°C before dissolving in DMSO-d6 (Euriso-Top, Saint-Aubin, France) for NMR analysis. Chemical shifts were given on ¤ scale and referenced to tetramethylsilane (TMS) at 0 ppm for 1 H-NMR (400 MHz) and 13 C-NMR (100 MHz). Assay with recombinant UGTs: Fraxetin glucuronidation was measured in reaction mixtures containing recombinant human UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17. The incubations were carried out as shown above for the HLM study. Three substrate concentrations (10, 100 and 500 µM) were used in this study: 500 and 100 µM were the approximate concentration at V max , and K m values for HLM, respectively; 10 µM was used to evaluate the catalytic activity of the UGT isoform(s) with a high affinity for fraxetin glucuronidation. All assays were conducted at 37°C for 60 min with the final protein concentration of 0.1 mg protein/ml. LC-UV and LC-ESI-MS detection was used to monitor the potential metabolites.
Chemical inhibition studies: Glucuronidation of fraxetin in pooled HLM was measured in the absence or presence of an inhibitor (niflumic acid, magnolol or fluconazole). Both niflumic acid and magnolol are selective inhibitors for UGT1A9. 10, 11) Fluconazol was reported to be a selective inhibitor of UGT2B7. 12) Two concentrations of 60 µM and 300 µM of fraxetin were incubated in the absence or presence of niflumic acid (10 µM), magnolol (1 µM) or fluconazole (500 µM) for M-1 and M-2, respectively. The incubations were performed for 15 min using a protein concentration of 0.05 mg/ml in HLM.
Kinetic study: The formation rates of fraxetin metabolites were linear over 30 min of incubation and 0.01 to 0.1 mg of microsomal protein. To ensure that less than 10% of substrate was metabolized in all incubations, the kinetic determinations were performed using a microsomal protein concentration of 0.025 mg/ml (HLM) with 15 min incubation. Fraxetin (6.25-1,200 µM) was incubated for estimating kinetic parameters in pooled HLM. For recombinant human UGTs, fraxetin (6.25-1,200 µM) was incubated with each isoenzyme for 15 min, and the final protein concentration was 0.025 mg/ml for UGT1A9 and 0.05 mg/ml for UGT1A1, UGT1A6, and UGT1A7. Kinetic parameters for fraxetin glucuronidation in HLM and UGTs were obtained by fitting experimental data to the Michaelis-Menten kinetics using Origin.
where V is the rate of reaction, V max is the maximum velocity, K m is the Michaelis constant (substrate concentration at 0.5 V max ), and [S] is the substrate concentration. Results are expressed as mean « S.E. of at least two experiments performed in triplicate.
Results
Characterization of fraxetin metabolites: Two product peaks (M-1 and M-2) were eluted at 8.5 min and 9.5 min, respectively, after incubation with fraxetin (100 µM) and HLM (0.5 mg/ml) in the presence of UDPGA (Fig. 2) . These two peaks were not detected in the blank incubations without UDPGA, or without fraxetin or without microsomes. These two metabolites were identified by LC-ESI-MS as showing identical product ions at m/z 383 in negative-ion mode (increasing m/z 176 compared with fraxetin), indicating that two metabolites were mono-glucuronides. The negative-ion mode was used because it is more sensitive than the positive-ion mode for fraxetin and its metabolites. These two metabolites can be completely hydrolyzed to the parent (fraxetin) by ¢-glucuronoside, implying that they are ¢-glucuronides. Furthermore, these two metabolites were further biosynthesized by liver microsomes and purified by LC, and then characterized by 1 H-NMR and 13 C-NMR. The 1 H-NMR and 13 C-NMR spectral data for the two mono-glucuronides are listed in Table 1 . Compared with NMR data for fraxetin, the 13 C-NMR spectrum of M-1 displayed the carbon signal of C-7 (¤ 131.1) shifted upfield to ¤ 132.7 (¦¤ ¹1.6), while the signals of C-6 and C-8 shifted downfield to 145.3 (¦¤ +0.1) and 142.6 (¦¤ +3.3), respectively, implying that M-1 should be fraxetin-7-O-glucuronide (F-7G). Similarly, the 13 C-NMR spectrum of M-2 showed that the carbon signal of C-8 shifted upfield to ¤ 136.6 (¦¤ ¹2.7), while the signals for C-7 and C-9 shifted downfield to 138.0 (¦¤ +5.3) and 143.6 (¦¤ +4.4), respectively, indicating that M-2 should be fraxetin-8-O-glucuronide (F-8G). Moreover, the coupling constants for the anomeric protons of M-1 (J = 7.8) and M-2 (J = 7.7) were characteristic of the ¢-anomers.
13,14)
Assay with recombinant human UGTs: Three substrate concentrations (10, 100, and 500 µM) were used for isoform screening to determine the involved human UGT isoforms in fraxetin glucuronidation. As shown in Figure 3 , UGT1A9 and UGT1A6 participated in the formation of F-8G, while other isoforms could not catalyze this biotransformation even at high substrate concentration (500 µM). In contrast, six human UGT isoforms were involved in the formation of M-1. UGT1A9,
Fig. 2. Representative HPLC-UV profile of fraxetin and its glucuronides in HLM
In Vitro Glucuronidation of FraxetinUGT1A1 and UGT1A7 catalyzed the formation of F-7G at low, medium and high substrate concentrations, while trace amounts of F-7G could be formed by 1A6, 1A8 and 1A10 (Fig. 3) at the high substrate concentration (500 µM). Compared to other isoforms, UGT1A9 displayed relative higher activities to the formation of both F-7G and F-8G.
Chemical inhibition assays: In order to reveal the importance of UGT1A9 in the formation of both F-7G and F-8G in HLMs, a series of inhibition assays was performed by using highly selective UGT1A9 inhibitors (niflumic acid and magnolol). As shown in Figure 4 , niflumic acid and magnolol displayed similar inhibitory effects on fraxetin glucuronidation. For the formation of F-7G (Fig. 4B) , the remaining activity of HLM was less than 70% in the presence of niflumic acid or magnolol, indicating that the contribution of UGT1A9 in the formation of F-7G was 30% at least. For the formation of F-8G (Fig. 4A) , the remaining activity of HLM was about 40% in the presence of niflumic acid or magnolol, indicating that UGT1A9 played an important role in the formation of F-8G. In addition, fluconazol had no effect on the formation of either F-7G or F-8G, indicating that UGT2B7 did not participate in fraxetin glucuronidation.
Kinetic characterization: The kinetic parameters including K m , V max and the intrinsic clearance (V max /K m ) for fraxetin glucuronidations in HLM and in major human UGTs isoforms were determined and are listed in Table 2 . The range of substrate concentrations for the kinetic studies was from 6.25 to 1,200 µM.
Over the whole concentration range tested, fraxetin glucuronidations in HLM and in human UGTs isoforms including UGT1A1, UGT1A6, UGT1A7 and UGT1A9, followed Michaelis-Menten kinetics, as evidenced by the Eadie-Hofstee plots (Fig. 5) . The kinetic parameters of M-1 in UGT1A6, UGT1A8 and UGT1A10 could not be well characterized, due to the formation rates of F-7G in these isoforms being very slow, and the amounts at lower substrate concentrations being less than the limits of quantification. In human liver microsomes, the K m values for the formation of F-7G and F-8G were 309.4 and 60.0 µM, respectively, while the V max values for the formation of F-7G and F-8G were 29.3 and 28.8 nmol/min/mg, respectively. The K m values for the formation of F-7G in recombinant UGT1A1, UGT1A7, and UGT1A9 were 85.2, 79.6, and 52.3 µM, respectively, and the corresponding V max values were 2.5, 2.1, and 2.2 nmol/min/mg, respectively. The K m values for the formation of F-8G values in recombinant UGT1A6, and UGT1A9 were 40.1, and 12.3 µM, respectively, and the corresponding V max values were 2.4 and 3.7 nmol/min/mg, respectively.
Discussion
It is well-known that most coumarin phenolics are good substrates of human UGTs. 7) 7-Hydroxycoumarin and 4-methylumbelliferone have been widely used as non-selective probes for evaluation of the activities of many UGT isoforms. 15) Our previous study investigated the glucuronidation pathways of daphnetin (7,8-dihydroxylcoumain) , and revealed that both the C-7 and the C-8 phenolic groups can be easily glucuronidated by human UGTs. The C-7 phenolic can be catalyzed unselectively by most members of UGT1As, while the C-8 phenolic of daphnetin is catalyzed selectively by UGT1A6 and UGT1A9. 7) In this study, we also found that only UGT1A6 and UGT1A9 were capable of catalyzing the fraxetin 8-O-glucuronidation, while at least six UGT1A isoforms were involved in its 7-O-glucuronidation. In addition, neither fraxetin nor daphnetin can be glucuronidated by the members of the UGT2B family. These findings agree well with the enzyme selectivity of daphnetin, indicating that the C-8 phenolic has higher UGT isoform selectivity compared to the C-7 phenolic in the glucuronidation of 7,8-dihydroxyl coumarins.
Compared to daphnetin, fraxetin has a methoxy group at the C-6 position, which may affect the turnovers of 7-O-and 8-Oglucuronidation. It is evident from Figure 2 and Table 2 that the C-8 phenolic is the preferential site of fraxetin in HLM, which differs from daphnetin producing two glucuronides with similar kinetic parameters and equivalent metabolic clearance. In HLM, the clearance (V max /K m ) of fraxetin 8-O-glucuronidation (480 µl/min/mg protein) is much higher than the 7-O-glucuronidation (94 µl/min/mg protein), but for daphnetin, the clearance of 7-Oglucuronidation (219 µl/min/mg protein) is slightly higher than the 8-O-glucuronidation (183 µl/min/mg protein). These results indicate that the presence of C-6 methoxy produces different effects on 7-O-and 8-O-glucuronidation. The addition of C-6 methoxy on 7,8-dihydroxylcoumarin decreases the clearance of F-7G while increases that of F-8G.
The large differences in the formation rate of F-7G and F-8G in HLM can be mainly attributed to the variations in metabolic contribution of UGT1A6 and UGT1A9. The addition of C-6 methoxy on 7,8-dihydroxylcoumarin significantly reduced the catalytic rates of UGT1A6 in the formation of both F-7G and F-8G, especially for 7-O-glucuronidation. Both of the inhibition assays and the kinetic characterization illustrated that UGT1A9 made a relatively important contribution in fraxetin 7-O-glucuronidation while UGT1A6 played a very limited role in this biotransformation. In contrast, UGT1A6 exhibited a high reaction rate of daphnetin7-O-glucuronidation compared to UGT1A9 (15.6 and 12.4 nmol/min/mg for UGT1A6 and UGT1A9, respectively). Furthermore, the addition of a C-6 methoxy group on 7,8-dihydroxylcoumarin increased the affinity of fraxetin on UGT1A9, especially for 8-O-glucuronidation. UGT1A9-mediated fraxetin 8-O-glucuronidation exhibited a lower K m value compared to UGT1A9-mediated daphnetin 8-O-glucuronidation (12.3 and 44.3 µM, respectively). Specifically, the substrate affinity on UGT1A9 was increased about 4 fold after the addition of C-6 methoxy on 7,8-dihydroxylcoumarin. These findings agreed well with several In Vitro Glucuronidation of Fraxetinreports published previously, in which UGT1A6 prefers polar phenolic compounds with small volume, 16) and the hydrophobic substitutes on the benzene ring could improve the affinity of substrate on UGT1A9. 17, 18) Taken together, fraxetin can be extensively metabolized by human UGTs and generates two mono-glucuronides (F-7G and F-8G). Both kinetic characterization and inhibition assay demonstrated that UGT1A9 played important roles in fraxetin glucuronidations, especially in the formation of the major metabolite F-8G. Considering that UGT1A9 is a major UGT isoenzyme expressed in human liver and kidney, the activities of fraxetin glucuronides (especially for F-8G) should be further investigated. 19, 20) However, the isolation and separation of these two glucuronides of fraxetin is very difficult; F-7G and F-8G have nearly identical retention behaviors in commonly used columns including ODS and silica columns even using sub-2 µm stationary phase particles. In this study, an uncommon column (a XAmide Hydrophilic interaction LC column prepared by Dalian Institute of Chemical Physics) was used after screening a series of LC columns with different solid phases. Structural variations in the HILIC (hydrophilic interaction liquid chromatography)-type stationary phases with chemically bonded amido ligands provide super hydrophilicity and selectivity compared with RPLC columns, which is important for the retention and separation of compounds with strong polarity. 21) In addition, the ratios of these two glucuronides of fraxetin generated in different species are also varied, due to the participating enzymes and their functions are quite different with species. In fact, we also found that the ratio of F-7G/F-8G in rat liver microsomes is larger than that in HLM, since rat ugt1A9 is a pseudogene and the propofol O-glucuronidation activity in rat liver is really lower than that in humans. 22, 23) 
